ATE526962T1 - Biotherapeutische zusammensetzung mit probiotischen escherichia coli und metronidazol und ihre verwendungen - Google Patents
Biotherapeutische zusammensetzung mit probiotischen escherichia coli und metronidazol und ihre verwendungenInfo
- Publication number
- ATE526962T1 ATE526962T1 AT07777134T AT07777134T ATE526962T1 AT E526962 T1 ATE526962 T1 AT E526962T1 AT 07777134 T AT07777134 T AT 07777134T AT 07777134 T AT07777134 T AT 07777134T AT E526962 T1 ATE526962 T1 AT E526962T1
- Authority
- AT
- Austria
- Prior art keywords
- metronidazole
- composition containing
- escherichia coli
- containing probiotic
- biotherapeutic composition
- Prior art date
Links
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000282 metronidazole Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000588724 Escherichia coli Species 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 230000000529 probiotic effect Effects 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 3
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000002389 Pouchitis Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80109606P | 2006-05-18 | 2006-05-18 | |
| PCT/US2007/011859 WO2007136719A2 (en) | 2006-05-18 | 2007-05-17 | Biotherapeutic compositions comprising probiotic escherichia coli and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526962T1 true ATE526962T1 (de) | 2011-10-15 |
Family
ID=38583035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07777134T ATE526962T1 (de) | 2006-05-18 | 2007-05-17 | Biotherapeutische zusammensetzung mit probiotischen escherichia coli und metronidazol und ihre verwendungen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090252708A1 (de) |
| EP (1) | EP2040724B1 (de) |
| JP (1) | JP2009537547A (de) |
| AT (1) | ATE526962T1 (de) |
| CA (1) | CA2652559A1 (de) |
| WO (1) | WO2007136719A2 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| JP2011503104A (ja) | 2007-11-09 | 2011-01-27 | カリフォルニア インスティテュート オブ テクノロジー | 免疫調節化合物ならびに関連組成物および方法 |
| WO2011044208A1 (en) * | 2009-10-06 | 2011-04-14 | Scott Dorfner | Antibiotic formulations providing reduced gastrointentestinal side effects |
| JP6027961B2 (ja) | 2010-04-07 | 2016-11-16 | シェン, ユエSHEN, Yue | 粘膜へ化合物を送るための媒体、それに関連する組成物、方法、及びシステム |
| SG187201A1 (en) * | 2010-07-26 | 2013-02-28 | Qu Biolog Inc | Immunogenic anti-inflammatory compositions |
| US9539281B2 (en) | 2011-07-12 | 2017-01-10 | The Brigham And Women's Hospital, Inc. | Lipid-containing PSA compositions, methods of isolation and methods of use thereof |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| EP2836224A4 (de) | 2012-02-29 | 2015-12-16 | Ethicon Endo Surgery Inc | Zusammensetzungen von biozönose und zugehörige verfahren |
| CN104159527B (zh) | 2012-03-06 | 2017-04-12 | 弗罗桑医疗设备公司 | 包含止血糊剂的压力容器 |
| RU2636240C2 (ru) | 2012-06-12 | 2017-11-21 | Ферросан Медикал Дивайсиз А/С | Сухая гемостатическая композиция |
| WO2013188529A1 (en) | 2012-06-15 | 2013-12-19 | Temple University Of The Commonwealth System Of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CA2911826C (en) | 2013-05-10 | 2022-08-23 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
| JP6390873B2 (ja) | 2013-06-21 | 2018-09-19 | フェッローサン メディカル ディバイス エー／エス | 減圧膨張させた乾燥組成物およびそれを保持するためのシリンジ |
| BR112016013322B1 (pt) | 2013-12-11 | 2020-07-21 | Ferrosan Medical Devices A/S | métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit |
| US10251946B2 (en) | 2014-05-02 | 2019-04-09 | Qu Biologics Inc. | Anti-microbial immunomodulation |
| BR112017007466B1 (pt) | 2014-10-13 | 2021-03-02 | Ferrosan Medical Devices A/S | método para preparar uma composição seca, método para reconstituir a composição seca, pasta, composição seca, recipiente, kit homeostático, e, uso de uma composição seca |
| CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| EP3400953A1 (de) | 2014-12-23 | 2018-11-14 | 4D Pharma Research Limited | Pirinpolypeptid und immunmodulation |
| AR103260A1 (es) | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | Modulación inmunitaria |
| RU2705905C2 (ru) | 2014-12-24 | 2019-11-12 | Ферросан Медикал Дивайсиз А/С | Шприц для удерживания и смешивания первого и второго веществ |
| WO2016201342A1 (en) | 2015-06-10 | 2016-12-15 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
| NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| SMT201900588T1 (it) | 2015-06-15 | 2019-11-13 | 4D Pharma Res Limited | Blautia stercoris e wexlerae per uso nel trattamento di malattie infiammatorie ed autoimmuni |
| WO2016203221A1 (en) | 2015-06-15 | 2016-12-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CA2986981A1 (en) | 2015-07-03 | 2017-01-12 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
| JP6918365B2 (ja) | 2015-08-19 | 2021-08-11 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 脂質化ｐｓａ組成物および方法 |
| CN108513545B (zh) | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| ME03487B (de) | 2016-03-04 | 2020-01-20 | 4D Pharma Plc | Zusammensetzungen mit bakteriellen blautia-stämmen zur behandlung von viszeraler überempfindlichkeit |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| US11491181B2 (en) | 2016-07-15 | 2022-11-08 | President And Fellows Of Harvard College | Glycolipid compositions and methods of use |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018183941A2 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with live biotherapeutics |
| DK3630136T3 (da) | 2017-05-22 | 2021-05-25 | 4D Pharma Res Ltd | Sammensætninger, der omfatter bakteriestammer |
| EP3630942B1 (de) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Zusammensetzungen mit bakterienstamm |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| SMT202000555T1 (it) | 2017-06-14 | 2020-11-10 | 4D Pharma Res Limited | Composizioni comprendenti un ceppo batterico del genere megaspaera e loro usi |
| SMT202000695T1 (it) | 2017-06-14 | 2021-01-05 | 4D Pharma Res Limited | Composizioni comprendenti ceppi batterici |
| JP2020532515A (ja) | 2017-08-30 | 2020-11-12 | ペンデュラム セラピューティクス， インコーポレイテッド | マイクロバイオーム関連障害の処置のための方法および組成物 |
| US20210247394A1 (en) * | 2018-04-25 | 2021-08-12 | Icahn School Of Medicine At Mount Sinai | Isolated bacterial strain for inducing proliferation or accumulation of regulatory t-cells |
| EP4321182A3 (de) | 2018-05-09 | 2024-05-29 | Ferrosan Medical Devices A/S | Verfahren zur herstellung einer hämostatischen zusammensetzung |
| EP3823651A4 (de) | 2018-07-19 | 2022-04-27 | Pendulum Therapeutics, Inc. | Verfahren und zusammensetzungen zur mikrobiellen transplantation |
| WO2021261626A1 (ko) * | 2020-06-25 | 2021-12-30 | 주식회사 인실리코 | 다당류 나노입자를 포함하는 장내 균총 개선용 신바이오틱스 조성물 |
| CN112514849A (zh) * | 2020-12-16 | 2021-03-19 | 安徽中医药大学 | 一种硫酸葡聚糖钠诱导白色念珠菌预先定植的结肠炎模型的构建方法 |
| CN112694992B (zh) * | 2020-12-30 | 2023-02-21 | 江南大学 | 一株可缓解腹泻的两歧双歧杆菌及其应用 |
| CN115350161B (zh) * | 2022-08-19 | 2024-04-16 | 沈阳药科大学 | 基于工程化益生菌外膜囊泡包被纳米酶递送系统及其制备方法和应用 |
| EP4663196A1 (de) | 2024-06-13 | 2025-12-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Entkolonisierung pathogener enterobakterien wie e. coli und/oder klebsiella pneumoniae aus dem darm unter verwendung von e. coli-stämmen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727028A (en) * | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
| AU2100402A (en) * | 2000-11-30 | 2002-06-11 | Bio Balance Corp | Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
-
2007
- 2007-05-17 EP EP07777134A patent/EP2040724B1/de not_active Not-in-force
- 2007-05-17 CA CA002652559A patent/CA2652559A1/en not_active Abandoned
- 2007-05-17 WO PCT/US2007/011859 patent/WO2007136719A2/en not_active Ceased
- 2007-05-17 US US12/227,435 patent/US20090252708A1/en not_active Abandoned
- 2007-05-17 JP JP2009511071A patent/JP2009537547A/ja active Pending
- 2007-05-17 AT AT07777134T patent/ATE526962T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090252708A1 (en) | 2009-10-08 |
| WO2007136719A3 (en) | 2008-05-29 |
| CA2652559A1 (en) | 2007-11-29 |
| WO2007136719A2 (en) | 2007-11-29 |
| JP2009537547A (ja) | 2009-10-29 |
| EP2040724B1 (de) | 2011-10-05 |
| EP2040724A2 (de) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE526962T1 (de) | Biotherapeutische zusammensetzung mit probiotischen escherichia coli und metronidazol und ihre verwendungen | |
| PH12020550941A1 (en) | Methods and compositions to prevent microbial infection | |
| RU2011150659A (ru) | Бактериоцин-продуцирующий lactobacillus и его применение в пищевых и фармацевтических композицях | |
| MXPA03002683A (es) | Cepas de escherichia coli las cuales sobreproducen l-treonina y procedimientos para produccion de l-treonina mediante fermentacion.. | |
| RU2010129158A (ru) | Способ очистки мерзлотных почв от нефти спорообразующими бактериями bacillus subtilis | |
| CY1119911T1 (el) | Βακτηριακα στελεχη απομονωθεντα απο χοιρους | |
| PH12019500360A1 (en) | Antibiotic compounds | |
| WO2007136553A3 (en) | Bacterial strains, compositions including same and probiotic use thereof | |
| WO2019175783A8 (en) | Compositions comprising bacterial strains and use thereof in controlling pathogenic microorganisms | |
| GB201013307D0 (en) | Anti-microbial metal organic framework | |
| WO2021203083A3 (en) | Composition comprising bacterial strains for improving metabolic health | |
| MY151204A (en) | Lactobacillus plantarum and uses thereof | |
| RU2009126450A (ru) | Штамм tbmi12 mscl p737 спорогенного микроорганизма bacillus smithii и применение его эндоспор в качестве пробиотика или пищевой добавки и пробиотическая композиция | |
| NZ591051A (en) | C7-fluoro substituted tetracycline compounds | |
| da Silva et al. | Uropathogenic Escherichia coli pathogenicity islands and other ExPEC virulence genes may contribute to the genome variability of enteroinvasive E. coli | |
| MX2021003084A (es) | Compuestos antibacterianos. | |
| WO2021261631A8 (ko) | 신규한 피칼리박테리움 프로스니치 eb-fpdk9 균주 및 그의 용도 | |
| Zhang et al. | Insights into the mobility and bacterial hosts of antibiotic resistance genes under dinotefuran selection pressure in aerobic granular sludge based on metagenomic binning and functional modules | |
| MX2023009332A (es) | Composiciones que comprenden exopolisacáridos y usos de las mismas. | |
| WO2008133659A3 (en) | Eschericia coli mutants and methods of use thereof | |
| MY208927A (en) | Bacterium for degrading sludge, bacterium degrading microorganism, microbial preparation and method and device for degrading sludge | |
| Xu et al. | Current knowledge on the dual species interaction and biofilm between Aspergillus and Bacillus: exploiting molecular understanding toward applications | |
| MX2009006808A (es) | Eliminacion e inhibicion del crecimiento del estafilococo aureus resistente a la meticilina mediante bacterias del acido lactico. | |
| TW200716162A (en) | Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria | |
| CN103232957A (zh) | 高效抑菌鼠李糖脂高产菌株及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |